Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy

Adeno-associated virus (AAV) was first characterized as small “defective” contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Bower, Jacquelyn J., Song, Liujiang, Bastola, Prabhakar, Hirsch, Matthew L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309980/
https://www.ncbi.nlm.nih.gov/pubmed/34201599
http://dx.doi.org/10.3390/v13071205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309980/
https://www.ncbi.nlm.nih.gov/pubmed/34201599
http://dx.doi.org/10.3390/v13071205

Ejemplares similares